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Dual Infection with Mycobacterium tuberculosis and
Pneumocystis jiroveci Lymphadenitis in a Patient with
HIV Infection: Case Report and Review of the Literature
THANA KHAWCHAROENPORN, M.D.,1 ANUCHA APISARNTHANARAK, M.D.,2
DUSSADEE SAKONLAYA, M.D.,3 LINDA M. MUNDY, M.D.,4,5
and THOMAS C. BAILEY, M.D.6

ABSTRACT
We report a case of dual Mycobacterium tuberculosis (TB) and Pneumocystis jiroveci (carinii)
(PCP) lymphadenitis in a patient with HIV who had been receiving trimethoprim-sulfamethoxazole (TMP-SMX) as systemic prophylaxis for PCP. This patient was successfully
treated with antituberculosis medications and TMP-SMX. Our review of the literature identified this as the first reported case of dual TB and PCP lymphadenitis in an HIV-infected
host and highlights the potential limitations of TMP-SMX prophylaxis.

INTRODUCTION

dence of 0.5%–2.5% in HIV-infected patients.4,5
The most common reported sites for disseminated pneumocystosis are the spleen, lymph
system, and liver. Less common sites include the
eye, ear canal, gastrointestinal tract, and skin.4,5
Concern has been raised that the incidence of extrapulmonary pneumocystosis might increase
with continued use of aerosolized pentamidine
for prophylaxis, although whether this is an associated risk remains inconclusive.4,6 We report
a case of abdominal lymphadenitis caused by
Mycobacterium tuberculosis (TB) and PCP coinfection in an HIV-infected patient who had been
receiving systemic prophylaxis for PCP. Furthermore, we report a review of the literature on

T

HIV PANDEMIC has been accompanied by
a dramatic increase in opportunistic infections in this patient population. Despite the
availability of combination antiretroviral therapy (ART) and effective opportunistic infection
prophylaxis, HIV-related opportunistic infections are prevalent in developing countries
where ART access is considerably difficult. In
Thailand, the three most common opportunistic
infections are tuberculosis, Pneumocystis jiroveci
(carinii) pneumonia (PCP) and cryptococcosis,
respectively.1–3 Reports of extrapulmonary
pneumocystosis are relatively rare with an inciHE
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PCP lymphadenitis in the HIV-infected population.
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was 61 cells/mm3 and the HIV RNA was
150,000 copies per milliliter. She was started on
GPOvir (stavudine, 30 mg; lamivudine, 150 mg;
and nevirapine, 200 mg) every 12 hours and
CASE REPORT
trimethoprim-sulfamethoxazole (TMP-SMX)
(160 mg/d of TMP) daily. On presentation to
A 30-year-old woman, diagnosed 1 month our hospital 1 month later, her temperature
earlier with HIV infection was admitted to our was 40°C, heart rate 90 beats per minute, reshospital with 1 week of intermittent high-grade piratory rate 20 breaths per minute, and blood
fever, night sweats, and generalized abdominal pressure 110/70 mm Hg. There was generalpain without nausea, vomiting, or diarrhea. In ized abdominal tenderness without guarding
the initial outpatient work-up, her CD4 count or rebound tenderness. Data revealed a normal
chest radiograph, total white blood cell count
of 12,100/mm3 (73% neutrophils, 13% lymA
phocytes, 12% monocytes, and 2% eosinophils),
hemoglobin 10.6 g/dL (reference, 12–14 g/dL),
aspartate aminotransferase 88 U/L [reference,
15–37 U/L], alanine aminotransferase 55 U/L
[reference, 30–65 U/L], alkaline phosphatase of
263 U/L [reference, 50–136 U/L] and lactate
dehydrogenase of 335 U/L [reference, 100–190
U/L.]. Serum amylase and lipase were normal.
Repeat CD4 count was 61 cells/mm3 and the
HIV RNA was 104 copies per milliliter. She reported complete adherence to GPOvir and
TMP-SMX and pill counts by our pharmacist
confirmed an accurate number of remaining
pills. In the initial work-up, a computed tomography (CT) scan of the abdomen showed
matted mesenteric and retroperitoneal lymphadenopathy (Fig. 1). A fine-needle aspiration
(FNA) of the retroperitoneal lymph nodes was
B
performed and aspirates were submitted for
mycobacterial and fungal cultures, histopathology, and polymerase chain reaction (PCR) for
PCP. Initial acid fast bacilli (AFB) staining revealed multiple AFB, with negative Gram’s
and Wright’s stains. Other special stains were
pending. She was initially treated with isoniazid (5 mg/kg per day), rifampicin (10 mg/kg
per day), pyrazinamide (25 mg/kg per day),
ethambutol (20 mg/kg per day) and azithromycin (500 mg/day). Because of the potential of drug interaction between rifampicin
and nevirapine, the ART regimen was switched
to stavudine 30 mg every 12 hours, lamivudine
150 mg every 12 hours and efavirenz 600 mg
daily. Two weeks into treatment, she had high
fevers, night sweats, and abdominal pain. The
FIG. 1. Abdominal computed tomography of this patient on admission revealed matted mesenteric and Gomeri methenamine silver (GMS) stains from
retroperitoneal lymph nodes (arrows).
the initial lynph node FNA became available,
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6 hours, stavudine (300 mg every 12 hours),
lamivudine (150 mg every 12 hours), efavirenz
(600 mg daily), and azithromycin (500 mg/
day). The lymph node aspirate’s culture grew
Mycobacterium tuberculosis susceptible to isoniazid, rifampicin, pyrazinamide, ethambutol,
streptomycin, quinolones, and other aminoglycosides. PCR for PCP was positive. Cultures for
bacteria and fungi and pathology for malignancy were all negative, and azithromycin was
discontinued. At follow-up 6 months after the
completion of therapy, there was no evidence
of ongoing infection and a repeat CT scan of
the abdomen revealed a significant reduction
in of the size and amount of intra-abdominal
and retroperitoneal lymphadenopathy.

DISCUSSION
FIG. 2. The cystic forms of Pneumocystis jiroveci (arrows)
are recognized from the foamy material stained with
Gomeri methenamine silver (GMS).

remarkable for multiple PCP cystic forms (Fig.
2) and TMP-SMX (15 mg/kg per day of TMP
divided every 6 hours) was initiated. Over the
next 4 days, the patient achieved dramatic clinical improvement and was discharged home on
isoniazid (5 mg/kg per day), rifampicin (10
mg/kg per day), pyrazinamide (25 mg/kg per
day), ethambutol (20 mg/kg per day), TMPSMX (15 mg/kg per day of TMP) divided every
TABLE 1.

Globally, PCP has been the most frequent
cause of HIV-related opportunistic infections
since the pandemic began; consistently the
most common clinical presentation remains
pneumonia.7 In Thailand, where the prevalence of TB is 0.5–2.0 per 1000 population, TB
is the most common HIV–related comorbid infection with an incidence of 30%, followed by
PCP (20%) and cryptococcosis (15%).2 Coinfection with TB and PCP has been rarely reported,
and when reported, is most often pulmonic.7
To our knowledge, this case is the first report
¡of dual infection with TB and PCP lymph-

CLINICAL FEATURES OF PREVIOUSLY PUBLISHED CASES OF PNEUMOCYSTIS JIROVECI LYMPHADENITIS AMONG
PATIENTS WHO HAD PRIOR HISTORY OF PCP AND THOSE WITHOUT A PRIOR HISTORY OF PCP

Characteristic
Diagnosis of AIDS
Median CD4 counts (cells/mm3)a
Clinical presentations
Chest symptomsb
Abdominal symptomsc
Nonspecific symptomsd
Asymptomatic
Survive

Patients with a prior history of PCP
(n  15)

Patients without a prior history of PCP
(n  10)

15 (100)
19

10 (100)
17

7
4
2
2
3

(47)
(26)
(13)
(13)
(20)

4
3
2
1
2

Data are number (%) of patients unless noted otherwise.
aData were available for 9 patients.
bIncluding the combinations of fever, cough, chest pain and/or dyspnea.
cIncluding the combinations of fever, abdominal pain, diarrhea, and/or abdominal distention.
dIncluding the combinations of fever, night sweat, weight loss.
PCP, Pneumocystis jiroveci (carinii) pneumonia.

(40)
(30)
(20)
(10)
(20)

4

adenitis and is most noteworthy given that the
patient had been receiving systemic TMP-SMX
PCP prophylaxis for the prior 30 days.
The diagnosis in this case was established after FNA, by demonstration of PCP cysts in the
aspirated lymph node, and by PCR. Recent
studies have identified that the most common
infectious causes of lymphadenopathy in HIVinfected patients were TB and Mycobacteriun
avium complex in 50%–60% of cases; malignancy, mainly lymphoma, Kaposi’s sarcoma
and PCP comprise the remainder of cases.8 In
dual PCP and HIV infection, the most common
extrapulmonary site of PCP is the intrathoracic
lymph nodes.8 PCP presenting as intra-abdominal lymphadenitis, as in our case, has rarely
been reported. Autopsy findings suggest that
dissemination of the extrapulmonary pneumocystosis has most likely occurred by either direct spread, hematogenously or the lymphatic
routes.9 Furthermore, PCR studies in animal
models have shown that extrapulmonary dissemination during the course of pneumocystosis is common.10
Atypical extrapulmonary pneumocystosis
have been reported with increasing frequency
since the onset of HIV/AIDS pandemic and an
increased frequency of extrapulmonary pneumocystosis has been noted among users of
aerosolized pentamidine.4 It has been suggested that aerosolized pentamidine distributes locally in the lungs and does not protect
against the systemic spread of PCP infection.8
To date, only two cases of extrapulmonary
pneumocystosis have been reported in patients
with AIDS who received systemic prophylaxis
for PCP with dapsone (100 mg/d) and pyrimethamine (25 mg/d).8 As the third case, this
patient had received TMP-SMX and reported
excellent ART and TMP-SMX adherence.
Per our literature review, we identify 24 additional cases of PCP lymphadenitis.8–29 All
cases had the diagnosis of AIDS, had CD4
counts less than 100 cells/L, and had multiple concurrent infectious sites, including the
lung, liver, spleen, kidney, adrenal glands, pituitary, choroid plexus, skin, and bone marrow.
The majority of cases had a prior history of
PCP (15/25; 60%), and were treated with intravenous pentamidine (8/25; 32%) and TMPSMX (7/25; 28%). Twelve patients (12/25; 48%)
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had a prior history of receiving aerosolized
pentamidine. Five patients had survived (5/25;
20%). There was no difference in the characteristics among those who had a prior history
of PCP and those without a prior history of PCP
(Table 1).
As a recognized limitation, we cannot exclude the possibility of existent indolent subclinical PCP infection at the time of TMP-SMX
initiation or drug malabsorption due to mesenteric TB. Although the patient developed PCP
and TB lymphadenitis within 1 month of initiating ART, because there was delay in immune
recovery, noted by the relatively unchanged
CD4 count and persistent HIV RNA, immune
reconstitution was unlikely.30
In summary, coinfection of TB and PCP lymphadenitis in HIV-infected patients is rare. The
diagnosis of concurrent infection of these two
organisms should be considered for patients
who have either one of these infections diagnosed and in whom lack of improvement or
clinical deterioration occurs despite appropriate treatment. This report is instructive for clinicians in that atypical presentations of PCP do
occur and emphasize the need for further evaluations in persistently ill hosts with advanced
HIV infection.
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